Tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease.
Moneycontrol News
@moneycontrolcom
Lupin shares gained a percent intraday Wednesday after the company launched drug that treats Huntington's chorea in the US.
The pharma major announced the launch of Tetrabenazine tablets, 12.5 mg and 25 mg in the US after receiving an approval from the United States Food and Drug Administration (FDA) earlier.
The drug is a generic equivalent of Valeant Pharmaceuticals North America, LLC's Xenazine tablets.
Tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease.
Xenazine tablets had annual sales of $153 million in the US, as per IQVIA MAT data in September 2018.
At 13:55 hours IST, the stock was quoting at Rs 852.75, up Rs 4.00, or 0.47 percent on the BSE.First Published on Nov 21, 2018 02:05 pm
